linjc16/ctgov huggingface dataset:
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.

Study Overview
=================
Brief Summary
-----------------
To further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.

Detailed Description
-----------------
A sequence polymorphism in patatin-like phospholipid domain containing protein 3 is significantly associated with nonalcoholic fatty liver disease, but its mechanism underlying this association remains obscure. We introduce the human samples of liver to clarify the relationship between the expression of plin5 and the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease, analyze the lipid metabolism and lipotoxicity of hepatocytes to elucidate the mechanisms of plin5 in the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease. Our study will contribute to the mechanism of nonalcoholic fatty liver disease, and its prevention and therapy.

Official Title
-----------------
the Role of plin5 in the Development of a Sequence Polymorphism in Patatin-like Phospholipid Domain Containing Protein 3 Polymorphism-associated Nonalcoholic Fatty Liver Disease

Conditions
-----------------
Non-alcoholic Fatty Liver Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: The diagnosis of simple fatty liver disease was confirmed by clinical presentation, ultrasound, and without long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases. Exclusion criteria: With long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The severity of non-alcoholic fatty liver disease | Evaluating by ultrasound the severity of non-alcoholic fatty liver disease | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The expression of plin5 | Evaluating by biochemical methods the expression of plin5 in patients liver tissue | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nonalcoholic fatty liver disease, Lipid droplets, Plin5
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the new formulation of Tobradex to the current approved formulation

Official Title
-----------------
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle

Conditions
-----------------
Post-surgical Inflammation

Intervention / Treatment
-----------------
* Drug: Tobradex (Antibiotic steroid combination)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for cataract extraction Exclusion Criteria: Under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tobradex (Antibiotic steroid combination)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anterior chamber inflammation |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aqueous cells and flare |  |  | 
| ocular pain |  |  | 
| physician's impression of infection |  |  | 
| frequency of treatment failures |  |  |
Hematopoietic Stem Cell Therapy in Chronic Wounds Using a Pressure Sore Model

Study Overview
=================
Brief Summary
-----------------
Aim of the study: Evaluation of feasibility, safety and potential effects of stem cells on chronic wounds using a pressure sore model. Clinical relevance: Accelerated healing of uncomplicated wounds Enhanced healing of complicated (chronic, non-healing) wounds Study design: Prospective controlled phase I/II study Cohort of 5 patients in pilot study, then reevaluation Patients: - Para- and tetraplegic patients with sacral pressure sores grade III-IVA according to the classification of Daniel and Seiler Methods: 1. First surgical intervention: Radical debridement of pressure sore Bone marrow harvest from the iliac crest Isolation of hematopoietic stem cells, aiming to gain > 1 mio. CD 34+ cells per patient under GMP conditions 3. Stem cell therapy (after 2 days) Injection of stem cells in suspension (50'000 CD 34+ cells in 100 microliter saline per cm2 of wound surface) on one half of the total wound surface and cell-free saline on the other half as a control 4. Second surgical intervention (after 3-4 weeks): Complete excision of the wound Closure of the defect by fasciocutaneous flap 5. Evaluation of wound healing: Clinical 3D laser imaging Histology Growth factor assay

Official Title
-----------------
Effect of Hematopoietic Stem Cells in Chronic Wounds Using a Pressure Sore Model: A Pilot Study on Feasibility, Safety and Potential Effects

Conditions
-----------------
Chronic Wounds, Pressure Sores, Hematopoietic Stem Cells, Wound Healing

Intervention / Treatment
-----------------
* Biological: Stem cell therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Para- or tetraplegic Sacral pressure sores Grade III-IV according to classification of Daniel and Seiler Exclusion Criteria: Diabetes mellitus Peripheral vascular disease Coronary artery disease Smoking Steroids and other immunosuppressive drugs Systemic autoimmune or rheumatoid diseases HIV Hepatitis B/C

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| feasibility, safety, efficacy |  | 1 yr | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic wounds, Pressure sores, Hematopoietic stem cells, Wound healing
SSRI and Buprenorphine

Study Overview
=================
Brief Summary
-----------------
This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Detailed Description
-----------------
Participants interested in receiving Buprenorphine will be offered the opportunity to enroll in this study. Enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. In this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). All participants will also be followed by their Buprenorphine clinic medical provider. Questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. Comparison(s): Participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.

Official Title
-----------------
Antidepressants During Office-Based Buprenorphine

Conditions
-----------------
Opiate Dependence, Depression

Intervention / Treatment
-----------------
* Drug: escitalopram
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: opiate dependence Ham-D > 14 Exclusion Criteria: no psychiatric contraindications to using escitalopram no medical contraindications to using escitalopram methadone dose < 30 no current SSRI use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo<br> | Drug: placebo<br>* placebo capsule/day for 3 months<br>|
| Active Comparator: escitalopram<br> | Drug: escitalopram<br>* 10mg escitalopram/day for 3 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Who Dropped Out of Buprenorphine Treatment | Drop-out is defined as 7 or more days of missed Buprenorphine doses | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Depressive Symptoms | Depressive symptoms, as measured by self-report during study interviews, using the Beck Depression Inventory II. Scores ranged from 0-63; higher scores indicate more depressive symptoms. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
opiate use, depression, buprenorphine, escitalopram
Ex Vivo Study of the Heracure Device for Intra-uterine Morcellation After Vaginal or Laparoscopic Hysterectomy

Study Overview
=================
Brief Summary
-----------------
Safety and performance evaluation of the Heracure Device for intra-uterine morcellation after vaginal or laparoscopic hysterectomy.

Detailed Description
-----------------
The purpose of this clinical investigation is to evaluate the safety and efficacy of the Heracure Device for intra-uterine morcellation after vaginal or laparoscopic hysterectomy.

Official Title
-----------------
Evaluation of the Heracure Device for Hysterectomy

Conditions
-----------------
Vaginal or Laparoscopic Hysterectomy

Intervention / Treatment
-----------------
* Device: Heracure Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is undergoing hysterectomy due to benign gynecologic disease Exclusion Criteria: Subject is not suspected of malignancy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intrauterine Morcellation of Uteri Post-Surgery<br>Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study) | Device: Heracure Device<br>* Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Device or procedure related Adverse Event (AE) | Adverse Event defined as uterine perforation at the end of procedure, assessed by inflating the uterus with saline. | Intra-operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Device Success | Device Success defined as the ability to reduce uterus size/circumference and the time required for performing the morcellation procedure | Intra-operation |
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

Study Overview
=================
Brief Summary
-----------------
In a retrospective study, the investigators will compare patients with locally advanced rectal cancer with high risk factors for failure who were treated with standard therapy or with total neoadjuvant therapy.

Official Title
-----------------
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

Conditions
-----------------
Rectal Cancer

Intervention / Treatment
-----------------
* Drug: Capecitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically proven locally advanced rectal cancer and the presence of one of the factors: T4, N2, positive mesorectal fascia, presence of extramural vascular invasion or presence of lateral lymph node. Exclusion Criteria: distant metastases, concomitant malignancy, inflammatory bowel disease, or malabsorption syndrome.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| total neoadjuvant therapy<br>Total neoadjuvant therapy consisted of 12 weeks of induction chemotherapy with CAPOX or FOLFOX, chemoradiotherapy with capecitabine and six to eight weeks of consolidation chemotherapy with CAPOX or FOLFOX prior to surgery. | Drug: Capecitabine<br>* comparison of two treatments<br>* Other names: oxaliplatin;|
| standard therapy<br>Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy) | Drug: Capecitabine<br>* comparison of two treatments<br>* Other names: oxaliplatin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pathological complete response | pathological complete response is defined as the absence of tumor cells in the surgical resection | during surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neoadjuvant rectal cancer score | Neoadjuvant rectal cancer score: The NAR score was calculated using the equation [5 pN - 3(cT - pT) + 12]^2 / 9.61 and further classified as low (< 8), intermediate (8-16), or high (< 16). | during treatment, assessed up to 10 days |
Conservative Treatment of Mallet Finger Injury

Study Overview
=================
Brief Summary
-----------------
Comparing outcomes of individuals treated with Kinesiotape and oval 8 versus quick cast for a conservatively managed mallet finger injury. Outcomes include DIP joint extension lag, patient satisfaction and function via the MHQ.

Official Title
-----------------
Prospective Randomized Clinical Trial Comparing Kinesiotape and Oval 8 to Quick Cast for Conservative Treatment of Mallet Finger Injury

Conditions
-----------------
Conservatively Treated Mallet Finger Injury

Intervention / Treatment
-----------------
* Other: Immobilization type for mallet injury


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: determined by a physician to require conservative treatment for a mallet finger injury, at least 18 years of age Exclusion Criteria: previous injury to the involved digit impacting ROM

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment with Kinesiotape and Oval 8<br> | Other: Immobilization type for mallet injury<br>* Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury<br>|
| Experimental: Treatment with quick cast<br> | Other: Immobilization type for mallet injury<br>* Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Goniometric measurement of range of motion for distal interphalangeal joint extension lag at the involved digit |  | 12 weeks from injury | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Goniometric measurement of range of motion for distal interphalangeal joint extension lag at the involved digit |  | 6 months post injury | 
| Brief Michigan Hand Outcome Questionnaire |  | 12 weeks from injury | 
| Brief Michigan Hand Outcome Questionnaire |  | 6 months post injury | 
| Satisfaction on a visual analog scale (0-10) |  | 12 weeks from injury | 
| Satisfaction on a visual analog scale (0-10) |  | 6 months post injury | 
| Goniometric measurement of range of motion deficit for distal interphalangeal joint flexion for involved digit |  | 12 week post injury | 
| Goniometric measurement of range of motion deficit for distal interphalangeal joint flexion for involved digit |  | 6 months post injury | 
| Pain according to a numeric pain rating scale (0-10/10) |  | 12 weeks after injury | 
| Pain according to a numeric pain rating scale (0-10/10) |  | 6 months post injury |
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.

Conditions
-----------------
Anemia, Cancer

Intervention / Treatment
-----------------
* Drug: Epoetin alfa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Body weight >/= 99lbs ECOG 0-2 Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women Exclusion Criteria: History of or concurrent second malignancy Evidence of primary or metastatic malignancy involving the Central Nervous System

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Epoetin alfa|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anemia, Cancer
24 Hour IOP Lowering Efficacy of AL-3789

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to describe the intraocular pressure-lowering efficacy of AL-3789 over a 24-hour period in patients with open-angle glaucoma compared to an untreated control. Patients received one treatment of AL-3789. Twenty-eight days after treatment, IOP was measured every 4 hours, beginning at 8 AM for 24 hours.

Conditions
-----------------
Open-angle Glaucoma

Intervention / Treatment
-----------------
* Drug: AL-3789 Sterile Suspension


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of open-angle glaucoma and treated for at least 30 days prior to Screening Visit with a topical prostaglandin analog as monotherapy. Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Pregnant, intend to become pregnant, breastfeeding. Difference in IOP greater than 3 mm Hg between eyes at Screening Visit. Any form of glaucoma other than open-angle glaucoma. Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AL-3789<br>AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye | Drug: AL-3789 Sterile Suspension<br>* Single administration by anterior juxtascleral depot<br>|
| No Intervention: No treatment<br>Fellow eye, as randomized | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Intraocular Pressure (IOP) |  | Day 28, Up to 24 hours |
Serial Measurement of Serum Antimullerian Hormone in Women Undergoing Laparoscopic Cystectomy of Endometrioma

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to study ovarian reserve after laparoscopic endometrioma cystectomy by measuring antimullerian hormone. The measurements were measured before the surgery and one week and three months after the surgery.

Detailed Description
-----------------
Antimullerian hormone will be obtained in patients with ovarian endometrioma before laparoscopic cystectomy is done. The measurements were compared with antimullerian hormone after one week and three months after the surgery. Forty three patients will be included in this study.

Official Title
-----------------
Serial Measurement of Serum Antimullerian Hormone in Women Undergoing Laparoscopic Cystectomy of Endometrioma

Conditions
-----------------
Endometriosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20-40 years ovarian endometrioma > or = 3 cms laparoscopic cystectomy treatment Exclusion Criteria: previous ovarian surgery other ovarian pathology previous drugs or hormonal treatment for endometrioma

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| endometrioma<br>ovarian endometrioma undergoing cystectomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ovarian reserve before and after ovarian endometrioma cystectomy. |  | one week and three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endometriosis, endometrioma, antimullerian hormone, cystectomy